Value, Access and Regulatory Strategy Workshop
Breakdown silos to facilitate increased access to new medicines
Leaders across industry and health authorities agree that finding answers to market access are critical to the future of delivering breakthrough medicines to patients. Unfortunately, policies and practice do not always marry up.
This meeting is the starting point to engage professionals working with value and regulatory strategies. HTA bodies and regulators are breaking down silos, facilitating access to new medicines and increasing efficiencies in assessment processes. R&D process will need to be able to generate evidence for registration and reimbursement.
Bringing together the policy makers and the policy implementers, to keep you ahead of the game of practical solutions.
Member Early-Bird: EUR 1230
Member Advance Rate: EUR 1330
Member Industry: EUR 1430
Non-Member Industry: EUR 1585
Member Government/Charitable/Non-profit/Academia (Full-Time): EUR 715
Non-member Government/Charitable/Non-profit/Academia (Full-Time): EUR 870
Speakers: Solange Corriol-Rohou (Senior Director, Globar RA & Policy, Astrazeneca), Angelika Joos (ED, Global Regulatory Policy, MSD), Katarzyna Kolasa (Senior Project Sales Director, Health Economics & Outcomes Research, GE Healthcare), Mira Pavlovic (Founder, MDT Services), Claudine Sapede (Global HTA & Payment Policy Lead, F. Hoffmann-La Roche)
Category: Conferences | Science, Health & Medicine | Pharmaceuticals